Ireland - English - HPRA (Health Products Regulatory Authority)

kowa pharmaceutical europe gmbh - pitavastatin calcium - film-coated tablet - 1 base milligrams - hmg coa reductase inhibitors; pitavastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

kowa pharmaceutical europe gmbh - pitavastatin calcium - film-coated tablet - 2 milligram(s) - hmg coa reductase inhibitors; pitavastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

kowa pharmaceutical europe gmbh - pitavastatin calcium - film-coated tablet - 4 milligram(s) - hmg coa reductase inhibitors; pitavastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

ethyx pharmaceuticals - fluvastatin - prolonged-release tablet - hmg coa reductase inhibitors; fluvastatin

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - lovastatin - tablet - lovastatin 20 mg - lipid modifying agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - fluvastatin sodium - oral capsule - 20mg

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - film-coated tablet - pitavastatin 1 mg - lipid modifying agents

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - film-coated tablet - pitavastatin 2 mg - lipid modifying agents

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - film-coated tablet - pitavastatin 4 mg - lipid modifying agents

Israel - English - Ministry of Health

teva israel ltd - pravastatin sodium - tablets - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels pravastatin is indicated to: - reduce the risk of recurrent myocardial infarction. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attack (tia). *hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).